Deciphex are pleased to announce the release of their first commercial digital pathology product. Patholytix Preclinical is the first built for purpose digital pathology solution for preclinical/toxicologic pathology in pharma and clinical research organisations.
Designed in conjunction with key industry collaborators with dedicated workflows for preclinical toxicologic pathology, Patholytix Preclinical also provides the best ergonomic experience for pathologists and facilitates slide review throughput in line with that achievable on a microscope.
To support prevailing business models in the industry, Deciphex has deployed industry leading security strategies in our architecture allowing safe and efficient interaction between distributed pharma sites and CROs.
“This is a breakthrough for Deciphex, launching our first commercial product less than 18 months following our foundation.”
says Dr Donal O’Shea, CEO.
“The pent-up demand for this product is unprecedented in my experience in the digital pathology industry and we plan to deploy immediately to a number of early adopters. We see this solution having the potential to disrupt the digital pathology content management space in pharma”
The company has also recently initiated a €2m EU funded Fast-track to Innovation program in conjunction with Janssen Pharmaceuticals and PDS to facilitate the optimisation, integration and validation of our patented AI based abnormality detection into the workflows of Patholytix. The integration of AI based pre-screening technologies will have a further significant impact on the productivity of fully digital peer and primary review processes.
For further information on Patholytix Preclinical or to schedule a demonstration, please contact email@example.com to news